


(Use several sheets if necessary)

Sheet 1 of 1

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM						<input type="checkbox"/>	<input type="checkbox"/>
AN						<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

<i>SJS</i>	AR	Ellis, et al., "Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src", J. Biol. Chem., Vol. 273(2), pp. 1052-1057 (1998)
	AS	
	AT	

EXAMINER SHERIDAN SWOPE, PH.D. DATE CONSIDERED JUL 27 2007
 PRIMARY EXAMINER

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

5/9/07

Substitute for form 1449/PTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

Sheet 1 of 1

COMPLETE IF KNOWN

Application Number	10/648,593
Filing Date	08/26/2003
First Named Inventor	FEI HUANG
Art Unit	1652
Examiner Name	SWOPE, SHERIDAN
Attorney Docket Number	D0273 NP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
<i>SG</i>	AA	<p>"Affimetrix GeneChip Human Genome U133 Array Set HG-U1233A", GEO, 11 March 2002 (2002-03-11), XP002254749</p> <p>Probe ID 203499_at, probe ID 212097_at, Probe ID 213426_s_at, probe ID 213503_x_at</p>	

Examiner Signature	SHERIDAN SWOPE, PH.D. PRIMARY EXAMINER	Date Considered	JUL 27 2007
-----------------------	---	--------------------	-------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

~~Substitute for form 1449/PTO~~

**JUL 11 2007 INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

1

of 2

COMPLETE IF KNOWN

Application Number	10/648,593
Filing Date	08/26/2003
First Named Inventor	FEI HUANG
Art Unit	1652
Examiner Name	SWOPE, SHERIDAN
Attorney Docket Number	D0273 NP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

SHERIDAN SWOPE PH.D.

JUL 27 2007

CHERIDAN SWOFF, PH.D. JUL 27 2007
Examiner Signature PRIMARY EXAMINER Date Considered

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

Sheet 2 of 2

COMPLETE IF KNOWN

Application Number	10/648,593
Filing Date	08/26/2003
First Named Inventor	FEI HUANG
Art Unit	1652
Examiner Name	SWOPE, SHERIDAN
Attorney Docket Number	D0273 NP

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

SHERIDAN SWOPE, PH.D.

Examiner Signature	PRIMARY EXAMINER	Date Considered	JUL 27 2007
-----------------------	------------------	--------------------	-------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

O I P E
(use several sheets if necessary)

Sheet 1 of 6

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003Group
1656

OCT 02 2006

PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

U.S. RELATED PATENT APPLICATIONS

EXAMINER INITIAL		U.S. APPLICATION	DATE OF FILING	NAME	CLASS	SUBCLASS	FILING DATE
<i>SS</i>	AA	10/348,119	1/17/03	Huang, et al.			
	AB	11/169,041	6/28/05	Huang, et al.			

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		U.S. APPLICATION	DATE OF FILING	NAME	CLASS	SUBCLASS	FILING DATE
<i>SS</i>	AC	2006/0029971 A1	2/9/06	Golub, et al.			
	AD	2005/0079518 A1	4/14/05	Baker, et al.			

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
	AG	WO00/62778	10/26/00	PCT <i>Duplicate</i>			<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

<i>SS</i>	AL	Aasheim, et al., "A Splice Variant of Human Ephrin-A4 Encodes a Soluble Molecule that is Secreted by Activated Human B Lymphocytes", Blood, Vol. 95(1), pp. 221-230 (2000)
	AM	Abraham, et al., "Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder", Clin. Cancer Res., Vol. 12(2), pp. 353-360 (2006)
<i>SS</i>	AN	Alves, et al., "EphA2 as Target of Anticancer Immunotherapy: Identification of HLA-A*0201-Restricted Epitopes", Cancer Res., Vol. 63, pp. 8476-8480 (2003)

EXAMINER **SHERIDAN SWOPE, PH.** PRIMARY EXAMINER DATE CONSIDERED *Jul 27 2007*

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003Group
1656

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Blume-Jensen, et al., "Oncogenic Kinase Signalling", Nature, Vol. 411, pp. 355-365 (2001)
2AB	Brantley, et al., "Soluble Eph A Receptors Inhibit Tumor Angiogenesis and Progression <i>in vivo</i> ", Oncogene, Vol. 21, pp. 7011-7026 (2002)
2AC	Brown, et al., "Regulation, Substrates and Functions of SRC", Biochimica et Biophys. Acta., Vol. 1287, pp. 121-149 (1996)
2AD	Cheng, et al., "Blockade of EphA Receptor Tyrosine Kinase Activation Inhibits Vascular Endothelial Cell Growth Factor-Induced Angiogenesis", Molec. Cancer Res., Vol. 1, pp. 2-11 (2002)
2AE	Davis, et al., "Ligands for EPH-Related Receptor Tyrosine Kinases That Require Membrane Attachment or Clustering for Activity", Science, Vol. 266, pp. 816-819 (1994)
2AF	de Saint-Vis, et al., "Human Dendritic Cells Express Neuronal Eph Receptor Tyrosine Kinases: Role of EphA2 in Regulating Adhesion to Fibronectin", Blood, Vol. 102(13), pp. 4431-4440 (2003)
2AG	Duxbury, et al., "Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness", Biochem. Biophysical Res. Comm., Vol. 320, pp. 1096-1102 (2004)
2AH	Fang, et al., "A Kinase-Dependent Role for EphA2 Receptor in Promoting Tumor Growth and Metastasis", Oncogene, Vol. 24, pp. 7859-7868 (2005)
2AI	Flanagan, et al., "The Ephrins and EPH Receptors in Neural Development", Annu. Rev. Neurosci, Vol. 21, pp. 309-45 (1998)
2AJ	Frame, M.C., "Src in Cancer: Deregulation and Consequences for Cell Behaviour", Biochimica et Biophys. Acta, Vol. 1602, pp. 114-130 (2002)
2AK	Gale, et al., "Eph Receptors and Ligands Comprise Two Major Specificity Subclasses and Are Reciprocally Compartmentalized during Embryogenesis", Neuron, Vo. 17, pp. 9-19 (1996)
2AL	Ganju, et al., "The Eck Receptor Tyrosine Kinase is Implicated in Pattern Formation during Gastrulation, hindbrain segmentation and limb development", Oncogene, Vol. 9, pp. 1613-1624 (1994)
2AM	Goldman-Wohl, et al., "Eph and Ephrin Expression in Normal Placental Development and Preeclampsia", Placenta, Vol. 25, pp. 623-630 (2004)
2AN	Herath, et al., "Over-Expression of Eph and Ephrin Genes in Advanced Ovarian Cancer: Ephrin Gene Expression Correlates with Shortened Survival", BMC Cancer, Vol. 6, pp. 144 (2006)

EXAMINER

SHERIDAN SWOPE, PH.D
PRIMARY EXAMINER

DATE CONSIDERED

JUL 27 2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 3 of 6

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003Group
1656

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	Herrem, et al., "Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma", Vol. 11, pp. 226-231 (2005)
3AB	Hess, et al., "VE-Cadherin Regulates EphA2 in Aggressive Melanoma Cells Through a Novel Signaling Pathway", Cancer Biol. Therapy, Vol. 5(2), pp. 228-233 (2006)
3AC	Holder, et al., "Eph Receptors and Ephrins: Effectors of Morphogenesis", Development, Vol. 126, pp. 2033-2044 (1999)
3AD	Hu, et al., "EphA2 Induction of Fibronectin Creates a Permissive Microenvironment for Malignant Cells", Mol Cancer Res., Vol. 2(10), pp. 533-540 (2004)
3AE	Hynes, N.E., "Tyrosine Kinase Signalling in Breast Cancer", Breast Cancer Res., Vol. 2, pp. 154-157 (2000)
3AF	Kalo, et al., "Signal Transfer by Eph Receptors", Cell Tissue Res., Vol. 298, pp. 1-9 (1999)
3AG	Kataoka, et al., "Correlation of EPHA2 Overexpression with High Microvessel Count in Human Primary Colorectal Cancer", Cancer Sci., Vol. 95(2), pp. 136-141 (2004)
3AH	Kikawa, et al., "Regulation of the EphA2 Kinase by the Low Molecular Weight Tyrosine Phosphatase Induces Transformation", J. Biol. Chem., Vol. 277(42), pp. 39274-39279 (2002)
3AI	Kinch, et al., "Overexpression and Functional Alterations of the EphA2 Tyrosine Kinase in Cancer", Clin. Exper. Metastasis, Vol. 20, pp. 59-68 (2003)
3AJ	Kinch, et al., "Predictive Value of the EphA2 Receptor Tyrosine Kinase in Lung Cancer Recurrence and Survival", Clin. Cancer Res., Vol. 9, pp. 613-618 (2003)
3AK	Koolpe, et al., "An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor", J. Biol. Chem., Vol. 277(49), pp. 46974-46979 (2002)
3AL	Kozlosky, et al., "Lerk-7: A Ligand of the Eph-Related Kinases is Developmentally Regulated in the Brain", Cytokine, Vol. 9(8), pp. 540-549 (1997)
3AM	Lindberg, et al., "cDNA Cloning and Characterization of <i>eck</i> , an Epithelial Cell Receptor Protein-Tyrosine Kinase in the <i>eph/elk</i> Family of Protein Kinases", Molec. Cell. Biol., Vol. 10(12), pp. 6316-6324 (1990)
3AN	Lombardo, et al., "Discovery of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide(BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays", J. Med. Chem., Vol. 47, pp. 6658-6661 (2004)

EXAMINER

SHERIDAN SWOPE, PH.D.

DATE CONSIDERED

JUL 27 2007

PRIMARY EXAMINER

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003Group
1656

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

4AA	Lu, et al., "EphA2 Overexpression Decreases Estrogen Dependence and Tamoxifen Sensitivity", Cancer Res., Vol. 63, pp. 3425-3429 (2003)
4AB	Macrae, et al., "A Conditional Feedback Loop Regulates Ras Activity Through EphA2", Cancer Cell, Vol. 8, pp. 111-118 (2005)
4AC	Miao, et al., "Activation of EphA2 Kinase Suppresses Integrin Function and Causes Focal-Adhesion-Kinase Dephosphorylation", Nature Cell Biol., Vol. 2, pp. 62-69 (2000)
4AD	Miyazaki, et al., "EphA2 Overexpression Correlates With Poor Prognosis in Esophageal Squamous Cell Carcinoma", Int. J. Cancer, Vol. 103, pp. 657-663 (2003)
4AE	Nakamoto, et al., "Diverse Roles for the Eph Family of Receptor Tyrosine Kinases in Carcinogenesis", Microscopy Research Tech., Vol. 59, pp. 58-67 (2002)
4AF	Nakamura, et al., "Epha2/Efna1 Expression in Human Gastric Cancer", Cancer Sci., Vol. 96(1), pp. 42-47 (2005)
4AG	Ogawa, et al., "The Ephrin-A1 Ligand and its Receptor, EphA2, are Expressed during Tumor Neovascularization", Oncogene, Vol. 19, pp. 6043-6052 (2000)
4AH	Paik, et al., "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer", New Eng. J. Med., Vol. 351(27), pp. 2817-2826 (2004)
4AI	Pandey, et al., "Characterization of a Novel Src-like Adapter Protein That Associates with the Eck Receptor Tyrosine Kinase", Vol. 270(33), pp. 19201-19204 (1995)
4AJ	Pandey, et al., "Activation of the Eck Receptor Protein Tyrosine Kinase Stimulates Phosphatidylinositol 3-Kinase Activity", J. Biol. Chem., Vol. 269(48), pp. 30154-30157 (1994)
4AK	Pandey, et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- α -Induced Angiogenesis", Science, Vol. 268, pp. 567-569 (1995)
4AL	Parri, et al., "EphrinA1 Repulsive Response is Regulated by an EphA2 Tyrosine Phosphatase", J. Biol. Chem., Vol. 280(40), pp. 34008-34018 (2005)
4AM	Pratt, et al., "Activation of the EphA2 Tyrosine Kinase Stimulates the MAP/ERK Kinase Signaling Cascade", Oncogene, Vol. 21, pp. 7690-7699 (2002)
4AN	Riss, et al., "Comparison of MTT, XTT, and Novel Letrazolium Compound MTS for In Vitro Proliferation and Chemosensitivity Assays", Mol. Biol. Cell, 3 (Suppl):184(a).

EXAMINER

SHERIDAN SWOPE, PH.D.
PRIMARY EXAMINER

DATE CONSIDERED

JUL 27 2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 5 of 6

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003Group
1656

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

5AA	Ruiz, et al., "The Expression of the Receptor-Protein Tyrosine Kinase Gene, <i>Eck</i> , is Highly Restricted during Early Mouse Development", <i>Mechanisms Develop.</i> , Vol. 46, pp. 87-100 (1994)
5AB	Saito, et al., "Expression of EphA2 and E-Cadherin in Colorectal Cancer: Correlation with Cancer Metastasis", <i>Oncology Rep.</i> , Vol. 11, pp. 605-61 (2004)
5AC	Sambrook, J. et al., <i>Molecular Cloning: A Laboratory Manual</i> , /First and Second Edition, Book 1, Cold Spring Harbor Laboratory Press, publ., pp. 1.93-1.104 (1989)
5AD	Sulman, et al., "ECK, a Human EPH-Related Gene, Maps to 1p36.1, a Common Region of Alteration in Human Cancers", <i>Genomics</i> , Vol. 40, pp. 371-374 (1997)
5AE	Tanaka, et al., "EphA2 Phosphorylates the Cytoplasmic Tail of Claudin-4 and Mediates Paracellular Permeability", <i>J. Biol. Chem.</i> , Vol. 280(51), pp. 42375-42382 (2005)
5AF	Thaker, et al., "EphA2 Expression is Associated with Aggressive Features in Ovarian Carcinoma", <i>Clin. Cancer Res.</i> , Vol. 10, pp. 5145-5150 (2004)
5AG	Walker-Daniels, et al., "Differential Regulation of EphA2 in Normal and Malignant Cells", <i>Amer. J. Path.</i> , Vol. 162(4), pp. 1037-1042 (2003)
5AH	Walker-Daniels, et al., "C-Cbl-Dependent EphA2 Protein Degradation is Induced by Ligand Binding", <i>Molecular Cancer Res.</i> , Vol. 1, pp. 79-87 (2002)
5AJ	Wands, et al., "High Affinity Monoclonal Antibodies to Hepatitis B Surface Antigen (HB ₈ Ag) Produced by Somatic Cell Hybrids", <i>Gastroenterology</i> , Vol. 80, pp. 225-32 (1981)
5AJ	Wang, et al., "Negative Regulation of EphA2 Receptor by Cbl", <i>Biochem. Biophys. Res. Comm.</i> , Vol. 296, pp. 214-220 (2002)
5AK	Wilkinson, D.G., "Eph Receptors and Ephrins: Regulators of Guidance and Assembly", <i>International Rev. Cytology</i> , Vol. 196, pp. 177-244 (2000)
5AL	Wilkinson, D.G., "Multiple Roles of EPH Receptors and Ephrins in Neural Development", Vol. 2, pp. 155-164 (2001)
5AM	Xu, et al., "EphA2: Expression in the Renal Medulla and Regulation by Hypertonicity and Urea Stress In Vitro and In Vivo", <i>Am. J. Physiol. Renal Physiol.</i> , Vol. 288, pp. F855-F866 (2005)
SAN	Xu, et al., "Roles of Eph Receptors and Ephrins in Segmental Patterning", <i>Phil. Trans. R. Soc. Lond. B.</i> , Vol. 355, pp. 993-1002 (2000)

EXAMINER

SHERIDAN SWOPE, PH.D.
PRIMARY EXAMINER

DATE CONSIDERED

JUL 27 2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003Group
1656

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

6AA	Yong, et al., "Molecular Profiling of CD34+ Cells Identifies Low Expression of CD7, Along with High Expression of Proteinase 3 or Elastase, as Predictors of Longer Survival in Patients with CML", Blood, Vol. 107(1), pp. 205-212 (2006)
6AB	Zelinski, et al., "Estrogen and Myc Negatively Regulate Expression of the EphA2 Tyrosine Kinase", J. Cell. Biochem., Vol. 85, pp. 714-720 (2002)
6AC	Zeng, et al., "High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia", Amer. J. Path., Vol. 163(6), pp. 2271-2276 (2003)
6AD	Zhou, R., "The Eph Family Receptors and Ligands", Pharmacol. Ther., Vol. 77(3), pp. 151-181 (1998)
6AE	NCBI Entrez Accession No. NM_004431 (gi:32967310), Hess, et al., August 13, 2006
6AF	
6AG	
6AH	
6AI	
6AJ	
6AK	
6AL	
6AM	
6AN	

EXAMINER

SHERIDAN SWOPE, PH.D.
PRIMARY EXAMINER


DATE CONSIDERED

JUL 27 2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Sheet 1 of 1

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593
APPLICANT
HUANG ET AL.
FILING DATE
AUGUST 26, 2003

Group
1656

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
CS	AA 2004/0106132 A1	6/3/04	Huang, et al.			
CS	AB 2006/0019284 A1	1/26/06	Huang, et al.			
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
CS	AM WO2004/020583A2	3/11/04	PCT			<input type="checkbox"/>	<input type="checkbox"/>
CS	AN WO2006/005035A2	1/12/06	PCT			<input type="checkbox"/>	<input type="checkbox"/>
CS	AO WO03/062395A2	7/31/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
CS	AP WO00/62778	10/26/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
CS	AQ WO2004/085388A2	10/7/04	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	
AS	
AT	

EXAMINER

SHERIDAN SWOPE, PH.D.
PRIMARY EXAMINER

DATE CONSIDERED

JUL 27 2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.